Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders

NCT02210858 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

31

Enrollment

NIH

Sponsor class

Conditions

Accelerated Phase of Disease
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Chronic Myelomonocytic Leukemia
Chronic Phase of Disease
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
Recurrent Disease

Interventions

OTHER: Laboratory Biomarker Analysis
DRUG: Tipifarnib

Sponsor

National Cancer Institute (NCI)